Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Data Resource Profile: The Cancer Public Library Database in South Korea.
Choi DW, Guk M, Kim H, Ryu KS, Kong HJ, Cha HS, Kim HJ, Chae H, Jeon YS, Kim H, Jung J, Im JS, Choi KS. Choi DW, et al. Among authors: im js. Cancer Res Treat. 2024 Apr 30. doi: 10.4143/crt.2024.207. Online ahead of print. Cancer Res Treat. 2024. PMID: 38697846 Free article.
Prediction of Cancer Incidence and Mortality in Korea, 2024.
Jung KW, Kang MJ, Park EH, Yun EH, Kim HJ, Kim JE, Kong HJ, Im JS, Seo HG. Jung KW, et al. Among authors: im js. Cancer Res Treat. 2024 Apr;56(2):372-379. doi: 10.4143/crt.2024.252. Epub 2024 Mar 11. Cancer Res Treat. 2024. PMID: 38487833 Free PMC article.
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2021.
Park EH, Jung KW, Park NJ, Kang MJ, Yun EH, Kim HJ, Kim JE, Kong HJ, Im JS, Seo HG; Community of Population-Based Regional Cancer Registries. Park EH, et al. Among authors: im js. Cancer Res Treat. 2024 Apr;56(2):357-371. doi: 10.4143/crt.2024.253. Epub 2024 Mar 13. Cancer Res Treat. 2024. PMID: 38487832 Free PMC article.
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial.
Khouri IF, Alzahrani K, Kantarjian H, Milton DR, Gulbis AM, Sasaki K, Jain N, Short NJ, Kadia T, Daher M, Rafei H, Im JS, Marin D, Olson AL, Popat U, Qazilbash M, Ramdial J, Rondon G, Srour S, Kebriaei P, Shpall E, Champlin R, Jabbour EJ. Khouri IF, et al. Among authors: im js. Am J Hematol. 2024 May;99(5):836-843. doi: 10.1002/ajh.27254. Epub 2024 Feb 23. Am J Hematol. 2024. PMID: 38400519 Clinical Trial.
Regional disparities in major cancer incidence in Korea, 1999-2018.
Park EH, Kang MJ, Jung KW, Park EH, Yun EH, Kim HJ, Kong HJ, Choi CK, Im JS, Seo HG. Park EH, et al. Among authors: im js. Epidemiol Health. 2023;45:e2023089. doi: 10.4178/epih.e2023089. Epub 2023 Oct 12. Epidemiol Health. 2023. PMID: 37857340 Free PMC article.
Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities.
Popat UR, Pasvolsky O, Bassett R Jr, Mehta RS, Olson A, Chen J, Alousi AM, Al-Atrash G, Bashir Q, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Saini N, Shigle TL, Srour SA, Ramdial JL, Rezvani K, Qazilbash MH, Andersson BS, Champlin RE, Shpall EJ. Popat UR, et al. Among authors: im js. Blood Adv. 2023 Oct 24;7(20):6196-6205. doi: 10.1182/bloodadvances.2023010850. Blood Adv. 2023. PMID: 37611156 Free PMC article. Clinical Trial.
174 results